Bone Abstracts

Osteogenesis imperfect (OI) is an inheritable bone disease with low bone mass, fragility, deformity and multiple fractures in skeletal tissues. Modulation of Wnt signalling components reportedly alleviates excessive bone and joint remodelling in various skeletal disorders. This study is undertaken to explore whether loss of Wnt inhibitor Dickkopf-1 (Dkk1) action affects bone formation or skeletal homeostasis in OI. In clinical vignettes, OI patients had severe osteoporosis (<e...

see P296....

Objective: It was proved that expansive pedicle screw (EPS) could significantly enhance immediate screw stability through mechanical expanding and compressing. However, there were little researches on growth of bone tissue around screw and dynamic screw stability in vivo in osteoporotic vertebrae. This study was designed to evaluate growth and microstructure of bone tissue around screw and fixation strength of screw in osteoporotic sheep lumbar vertebrae.<p class=...

Introduction: Tumor-induced osteomalacia (TIO) is a rare acquired paraneoplastic syndrome which is usually induced by mesenchymal tissue tumor with excessive secretion of FGF23. The misdiagnosis of TIO is frequently seen in clinic. Therefore, this study is aimed to describe the misdiagnosed situation of TIO, explore the possible underlying reasons for missed diagnosis and misdiagnosis through the analysis of 144 TIO patients, and improve clinicians’ awareness of TIO.<...

Objective: To comparing the role of interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-α) in fat and bone communication.Methods: Male wild type (WT) mice, IL-6 knockout (IL-6−/−) mice, and tumor necrosis factor alpha (TNF-α) were fed with either standard diet (SD) or high fat diet (HFD) for 12 weeks. Bone mass and bone microstructure were evaluated by micro-CT. Gene expression related to lipid and bone metabolisms ...

Introduction: Femoral neck fractures and trochanteric fractures are two major types of hip fractures. The BMD changing or hip strength analysis (HSA) of the two type fractures may be different. No research had focused on a large sample of Asian people. This study investigated the differences in BMD and morphologic features of the two type hip fractures of elderly Asian people from QCT.Methods: A total of 279 elderly Chinese patients with hip fractures du...

Background: Cleidocranial dysplasia (CCD) is an autosomal-dominant skeletal dysplasia syndrome characterized by delayed closure of cranial sutures, remained-open fontanels, hypoplastic clavicles, abnormal dentition including retention of the primary teeth and delayed eruption of secondary dentition, and short stature. The responsible gene for CCD is RUNX2, which encodes an important transcription factor for osteoblast development and bone formation. CCD is caused by t...

Camurati-Engelmann disease (CED) is a rare autosomal dominant bone disease with transforming growth factor-β1 (TGFβ1) gene mutation. In order to expand our limited knowledge of Chinese CED patients, we reported eight Chinese families (11 patients) diagnosed with CED. The study was approved the Department of Scientific Research of Peking Union Medical College Hospital. All the patients were evaluated genetically, clinically, biochemically and radiographically...

X-linked hypophosphatemic osteomalacia (XLH) is an inherited skeletal disorder. The pathogenesis of the disease is fibroblast growth factor 23 (FGF23) induced renal phosphate wasting, hypophosphatemia and inappropriate lower 1, 25-dihydroxy-vitamin D3 concentration, which lead to impaired bone mineralization. There are only a few studies focus on phenotype of XLH patients in adulthood. Therefore, this cross-sectional study systematically described anthropometric, cl...

Background: There are no models for estimating risk of fracture in patients taking treatments for osteoporosis. Knowing a patient’s risk of fracture during treatment may help make future treatment decisions; therefore, the development of on-treatment fracture risk models is needed.Methods: To assess on-treatment fracture risk, the analysis included subjects who received denosumab (DMAb) 60 mg Q6 every 6 months for at least 1 year in either FREEDOM o...